PPT-James Yarmolinsky, PhD Drug-target Mendelian randomization and dementia risk

opportunities and challenges Advanced Research Fellow Department of Epidemiology and Biostatistics Imperial College London Conventional pharmacoepidemiological studies Numerous cardiometabolic medications eg lipidlowering antidiabetic antihypertensive have been linked to dementia risk. Kari Lock Morgan. Department of Statistical Science, Duke University. kari@stat.duke.edu. . with Robin Lock, Patti Frazer Lock, Eric Lock, Dennis Lock. Statistics: Unlocking the Power of Data. Wiley Faculty Network. Kari Lock Morgan. Department of Statistical Science, Duke University. kari@stat.duke.edu. . with Robin Lock, Patti Frazer Lock, Eric Lock, Dennis Lock. Statistics: Unlocking the Power of Data. Wiley Faculty Network. invalid instruments:. Egger regression and Weighted Median Approaches. David Evans. What is the problem?. Mendelian. Randomization (MR) uses genetic variants to test for causal relationships between phenotypic exposures and disease-related outcomes. David Evans. Some Criticisms of GWA Studies…. So you have a new GWAS hit for a disease… so what!?. You can’t change people’s genotypes (at least not yet). You can however modify people’s environments…. David Evans. University of Queensland. University of Bristol. Some Criticisms of DOC Modelling in Twins. Measurement error. Power (both variables need to have radically different aetiologies). Only useful for testing strong hypotheses about causation. David X. Cifu, MD Associate Dean for Innovation and System Integrations Professor and Chair, Department of PM&R Virginia Commonwealth University School of Medicine Senior TBI Specialist, U.S. Departm Civic Family Health Team. September 4, 2013. (based on a presentation developed by Dr. Michael Malek). (with liberal quoting from UpToDate). Disclosures. I have no financial or other ties to the pharmaceutical industry. Head of dementia services . Independent Nurse Prescriber. Steven.roberts@lpt.nhs.uk. . Lincolnshire Partnership NHS Foundation Trust. Aims of the Session. What is dementia?. The different types.. The risk factors?. Age (greatest risk factor). Vascular risk factors: HTN, DM, CVD, stroke, smoking, dyslipidemia . Genetics: apo E genotype (late AD), PSEN1, PSEN2, APP (early AD) . Recurrent TBI or head trauma . Drugs: . the future is now. Robert Plenge, MD, PhD. Broad Institute. Medical and Population Genetics (MPG). October 1, 2015. The Problem. http://. csdd.tufts.edu. /. Phase II/III failures drive high cost of drug development. es in the cognitive performance between benzodiazepine users and non-users.e safety of benzodiazepines has remained uncertain due to the inconsistent results of previous studies and the unknown m Robert Plenge, MD, PhD. ASBMR. September 15, 2016. Our two fundamental challenges. Cost. to develop an asset has increased by . 1/3. rd. since 2010. Average peak . sales. per asset has . halved since 2010. Cecilia Craig. Education Officer. Dementia Services Information & Development Centre. Alzheimer's . Disease (60%). Korsakoff. ’. s Dementia. Vascular . Dementia (20%). Lewy. Body . Dementia (15%). . While some risk factors for dementia can’t be changed, there are many ways you can . reduce your overall dementia risk..  . Follow . as many of these . 10 evidence-based . actions. . as you can to.